[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
Status:
Terminated
Trial end date:
2019-07-05
Target enrollment:
Participant gender:
Summary
This was a Phase II, multi-center, open label, single dose study in patients with tumor types
known to overexpress Gastrin-Releasing Peptide Receptor (GRPR), including breast, prostate,
colorectal, Non-Small Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC).